Agenus Inc. (NASDAQ:AGEN) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET

Company Participants

Zack Armen - Head, IR

Dr. Garo Armen - Chairman & CEO

Dr. Steven O'Day - Chief Medical Officer

Christine Klaskin - Vice President of Finance

Conference Call Participants

Emily Bodnar - H.C. Wainwright

Mike King - EF Hutton

Mayank Mamtani - B. Riley

Matt Phillips - William Blair

Operator

Good day, and welcome to the Agenus First Quarter 2023 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] And finally, I would like to advise all participants that this call is being recorded.

I'd now like to welcome Mr. Zach Arman to begin the conference. Zach, over to you.

Zack Armen

Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay.

I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and time lines, as well as time lines for data release and partnership opportunities. These statements are subject to risks and uncertainties, and we refer you to our SEC filings for more details on these risks.

Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Steven O'Day, Chief Medical Officer; and Christine Klaskin, Vice President of Finance.

Now, I'd like to turn the call over to Garo to highlight our progress and speak to our outlook for the remainder of the year. Garo?

Dr. Garo Armen

Good morning, everyone, and thank you for joining us for our first quarter 2023 update. Today, we'll primarily focus on the significant progress we've made with our groundbreaking botensilimab program and its potential to transform cancer treatment across nine different solid tumor types that we've reported on so far. Over the past 10 months, we've presented data at the plenary or late breaking sections of five major company, including ESMO-GI, SITC, ASCO-GI, SGO and CTOS. We look forward to sharing further insights at upcoming conferences such as ASCO in June and ESMO-GI in July.

Botensilimab, our innovative and multi-functional CTLA-4 anybody aims to revolutionize cancer treatment by extending clinical benefit to cold tumors, which have historically been unresponsive to standard-of-care and other immunotherapy agents, including other CTLA-4 anybody. And, impressively, botensilimab has demonstrated clinical responses in both cold and hot tumors. In a diverse patient population of nearly 400 individuals, across nine solid tumor types, all of them had exhausted prior treatment options botensilimab has made significant strides in eliciting responses, offering renewed hope for those who have failed all other available treatments.